Survivorship and prognosis in myelofibrosis with myeloid metaplasia

Figures & data

Table I.  Prognostic scoring systems in transplant-eligible patients (age <60 years from Dingli et al. [12] and ≤55 years from Cervantes et al. [10]) with agnogenic myeloid metaplasia.

	Risk category	Score sum	Median survival (months)	Score for Hgb <10 g/dl	Score for WBC 4 < or >30 × 10^9/l	Score for Plt <100 × 10^9/l	Score for constitutional symptoms	Score for circulating blasts ≥1%
Dingli et al. [13]	Low	0	155	1	1	1	NA	NA
	Intermediate	1	69
	High	≥2	24
Cervantes et al. [10]	Low	0 or 1	176	1	NA	NA	1	1
	High	≥2	33

Hgb, hemoglobin; WBC, white blood cell count; Plt, platelet count. Adapted with permission [14].

Strasser-Weippl K, Steurer M, Kees M, Augustin F, Tzankov A, Dirnhofer S, et al. Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma 2006; 47: 441–450

 PubMed Web of Science ®Google Scholar

Cervantes F, Barosi G, Demory J L, Reilly J, Guarnone R, Dupriez B, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102: 684–690

 PubMed Web of Science ®Google Scholar

Dingli D, Schwager S M, Mesa R A, Li C -Y, Tefferi A. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer 2005, in press

 PubMed Web of Science ®Google Scholar

Tefferi A. New insights into the pathogenesis and drug treatment of myelofibrosis. Curr Opin Hematol 2006, in press

 Web of Science ®Google Scholar